ERBB3 G284R
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ERBB3
Variant G284R
Impact List missense
Protein Effect unknown
Gene Variant Descriptions ERBB3 (HER3) G284R lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). G284R results in increased phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2)-expressing cells relative to wild-type Erbb3 (Her3) (PMID: 23680147), leads to increased cell proliferation in Erbb2 (Her2)-overexpressing cells in culture (PMID: 29963236), and results in a modest increase in Erbb2 phosphorylation and IL3-independent growth when expressed with ERBB2 (HER2) V956R in culture (PMID: 38806620), but has not been individually characterized and therefore, its effect on Erbb3 (Her3) protein function is unknown.
Associated Drug Resistance
Category Variants Paths

ERBB3 mutant ERBB3 G284R

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_001982.4
gDNA chr12:g.56088138G>A
cDNA c.850G>A
Protein p.G284R
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001982 chr12:g.56088138G>A c.850G>A p.G284R RefSeq GRCh38/hg38
NM_001982.4 chr12:g.56088138G>A c.850G>A p.G284R RefSeq GRCh38/hg38
NM_001982.3 chr12:g.56088138G>A c.850G>A p.G284R RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB3 G284R Advanced Solid Tumor sensitive Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). 23680147
ERBB3 G284R Advanced Solid Tumor sensitive Duligotuzumab Preclinical Actionable In a preclinical study, MEHD7945A inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). 23680147
ERBB3 G284R Advanced Solid Tumor sensitive Trastuzumab Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). 23680147
ERBB3 G284R Advanced Solid Tumor sensitive Pertuzumab Preclinical Actionable In a preclinical study, Perjeta (pertuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). 23680147
ERBB3 G284R Advanced Solid Tumor resistant Cetuximab Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB3 (HER3) G284R demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 23680147). 23680147
ERBB3 G284R Advanced Solid Tumor sensitive Pictilisib Preclinical Actionable In a preclinical study, the PI3K inhibitor GDC-0941 inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). 23680147
ERBB3 G284R Advanced Solid Tumor sensitive Mirdametinib + Pictilisib Preclinical Actionable In a preclinical study, the combination of GDC-0941 and Gomekli (mirdametinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) G284R (PMID: 23680147). 23680147
ERBB3 G284R transitional cell carcinoma sensitive Afatinib Case Reports/Case Series Actionable In a Phase II trial, a patient with urothelial carcinioma harboring ERBB3 G284R demonstrated stable disease for 7 months when treated with Gilotrif (afatinib) (J Clin Oncol 33, 2015 (suppl 7; abstr 312)). detail...
ERBB3 G284R urinary bladder cancer sensitive Afatinib Case Reports/Case Series Actionable In a Phase II clinical trial, a patient with ERBB3 G284R mutant urothelial carcinoma had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931). 27044931
ERBB3 G284R breast cancer predicted - sensitive Lapatinib + Trastuzumab Case Reports/Case Series Actionable In a clinical case study, the combination treatment of Herceptin (trastuzumab) and Tykerb (lapatinib) in a patient with breast cancer harboring ERBB3 (HER3) G284R resulted in antitumor efficacy, demonstrating a complete metabolic response after day 14 of treatment, a partial response after 8 weeks of treatment, and no clinical evidence of disease after 40 weeks of treatment (PMID: 25953157). 25953157
ERBB3 G284R breast cancer sensitive Patritumab deruxtecan Preclinical - Cell culture Actionable In a preclinical study, Patritumab deruxtecan (U3-1402) treatment inhibited growth of a breast cancer cell line expressing ERBB3 (HER3) G284R in culture (PMID: 35503762). 35503762
ERBB3 G284R Her2-receptor positive breast cancer predicted - sensitive Neratinib + Palbociclib Case Reports/Case Series Actionable In a Phase I trial, treatment with the combination of Nerlynx (neratinib) and Ibrance (palbociclib) resulted in an objective response rate of 16.7% (5/30, all partial responses) and clinical benefit rate of 26.7% in patients with advanced solid tumors harboring HER alterations, including a partial response in a patient with ESR1-positive, ERBB2 (HER2)-positive breast cancer harboring ERBB3 G284R (PMID: 41223631; NCT03065387). 41223631